New drug plus chemotherapy for untreated peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new drug (BEBT-908) combined with standard chemotherapy for people with untreated peripheral T-cell lymphoma. The goal is to see if the combination helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with peripheral T-cell lymphoma (PTCL) and have not yet received any treatment for it.
- You are between 18 and 75 years old.
- You are able to care for yourself (ECOG performance status 0-2).
- You have at least one tumor that can be measured on a scan.
- Your blood counts and organ function are within acceptable ranges.
- No major heart rhythm problems, recent bleeding, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
This trial tests a combination of four chemotherapy drugs for people with a type of lymphoma called peripheral T-cell lymphoma who have not had treatment before. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
Hear when a new Previously Untreated Peripheral T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.